#United States #New York #Pomerantz #Ultragenyx #RARE

Pomerantz Law Firm's Investigation into Ultragenyx Pharmaceutical

The Pomerantz Law Firm, a prominent figure in corporate securities litigation, has recently initiated an investigation regarding claims from investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The firm aims to determine whether Ultragenyx—as well as certain officers and directors—have engaged in unlawful practices that could adversely affect shareholder interests.

Background of the Investigation

On July 9, 2025, both Ultragenyx and its partner, Mereo BioPharma Group plc, announced the development status of their ongoing clinical study concerning UX143 (setrusumab), particularly in pediatric and young adult patients diagnosed with osteogenesis imperfecta (OI). This news was awaited keenly by investors, particularly as it involved a randomized, placebo-controlled Phase 3 trial, a critical phase in drug development that determines the efficacy and safety of a new medication.

However, only a day later, on July 10, Ultragenyx's stock experienced a significant drop. The share price plummeted by $10.41—about 25.11%—closing at $31.04. This drastic decrease raised alarms among investors, who are encouraged to contact Pomerantz to join a class action against the company if they believe their interests have been compromised.

Legal Implications and Possible Outcomes

The Pomerantz Law Firm, distinguished for its advocacy in cases of corporate misconduct and securities fraud, is leading this investigation with a strong track record. The firm was founded by Abraham L. Pomerantz, who is credited as a pioneer in the field of securities class action lawsuits. Over the past 80 years, they have acquired substantial settlements for victims of corporate malfeasance, ensuring investor rights are protected against illegal activities by company officers.

As investigations advance, the primary focus for Pomerantz is whether Ultragenyx officials misrepresented information related to the Orbit study or failed to disclose any pertinent risks that might have influenced their stock's value. The outcomes of these inquiries could lead not only to financial repercussions for Ultragenyx but also possibly involve higher regulatory scrutiny regarding their clinical trial processes and financial disclosures moving forward.

How to Get Involved

Investors who believe they have valid claims against Ultragenyx are encouraged to reach out directly to Danielle Peyton at Pomerantz Law Firm. This is an essential step for anyone who concerns themselves with their financial interests in light of the recent stock volatility and impending results from the Orbit study’s analysis.

The firm's contact details are as follows: 646-581-9980, ext. 7980, or via email at [email protected]. Investors may also seek more information regarding the potential class action by visiting the Pomerantz website.

Conclusion

The investigation by Pomerantz Law Firm represents a crucial effort to hold Ultragenyx Pharmaceutical and its leadership accountable for possible securities fraud. As the company navigates the complexities of clinical trials and investor expectations, stakeholders closely monitor developments. The advocacy from Pomerantz reinforces the importance of transparency and lawful practices in maintaining investor trust and corporate integrity.